PALI
Palisade Bio, Inc.NASDAQHealthcare$1.89+2.12%ClosedMarket Cap: $313.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.83
P/S
0.00
EV/EBITDA
-10.35
DCF Value
$2.39
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-47.8%
ROA
-12.5%
ROIC
-13.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-10.0M | $-8.9M | $-0.06 | — |
| FY 2025 | $0.00 | -Infinity% | $-18.1M | $-16.8M | $-0.30 | — |
| Q3 2025 | $0.00 | NaN% | $-2.9M | $-2.9M | $-0.38 | — |
| Q2 2025 | $0.00 | NaN% | $-2.8M | $-2.8M | $-0.58 | — |
| Q1 2025 | $0.00 | NaN% | $-2.3M | $-2.2M | $-0.46 | — |
| Q4 2024 | $0.00 | NaN% | $-3.4M | $-3.3M | $-0.39 | — |
| FY 2024 | $0.00 | NaN% | $-14.9M | $-14.4M | $-10.19 | — |
| Q3 2024 | $0.00 | NaN% | $-3.6M | $-3.5M | $-2.32 | — |
| Q2 2024 | $0.00 | NaN% | $-4.2M | $-4.1M | $-3.32 | — |
| Q1 2024 | $0.00 | -Infinity% | $-3.7M | $-3.5M | $-4.59 | — |
| Q4 2023 | $0.00 | NaN% | $-3.2M | $-3.0M | $-0.32 | — |
| FY 2023 | $250.0K | 100.0% | $-13.1M | $-12.3M | $-27.01 | — |